Retatrutide is a new pharmaceutical in the fight against obesity. This novel drug, belonging to a dual GLP-1 and GIP receptor agonist, shows promising results in clinical trials. By stimulating these receptors, Retatrutide suppresses appetite, {promotesinsulin secretion, and ultimately leads to significant weight loss. While further investigations